Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K1 | Q02750 | 19/20 | 0.51 |
| ▸ | MAP2K2 | P36507 | 4/20 | 0.51 |
| ▸ | PRKCZ | Q05513 | 1/20 | 0.51 |
| ▸ | IARS2 | Q9NSE4 | 1/20 | 0.51 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25378481 | 0.88 | MAP2K1 (0.50) | MAP2K1MAP2K2PRKCZIARS2NUDT1 | |
| SCHEMBL25378485 | 0.88 | MAP2K1 (0.50) | MAP2K1MAP2K2PRKCZIARS2NUDT1 | |
| SCHEMBL25380485 | 0.88 | MAP2K1 (0.50) | MAP2K1MAP2K2PRKCZIARS2NUDT1 | |
| SCHEMBL25380027 | 0.86 | MAP2K1 (0.51) | MAP2K1MAP2K2PRKCZIARS2NUDT1 | |
| SCHEMBL26196745 | 0.85 | NUDT1 (0.43) | MAP2K1MAP2K2PRKCZIARS2NUDT1 | |
| SCHEMBL30563772 | 0.84 | GAA (0.47) | MAP2K1MAP2K2PRKCZIARS2NUDT1 | |
| SCHEMBL25380486 | 0.84 | GAA (0.47) | MAP2K1MAP2K2PRKCZIARS2NUDT1 | |
| SCHEMBL25378201 | 0.82 | MAP2K1 (0.43) | MAP2K1MAP2K2PRKCZIARS2 | |
| SCHEMBL30563759 | 0.81 | MAP2K1 (0.42) | MAP2K1MAP2K2PRKCZIARS2NUDT1 | |
| SCHEMBL25381506 | 0.81 | RAB9A (0.43) | NUDT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250250293-A1 | INHIBITORS OF MEK KINASE | MOSAICA MEDICINES, INC. | 2025-08-07 | — | — | US | claimed |
| US-12122800-B2 | Inhibitors of MEK kinase | KINNATE BIOPHARMA INC. (US) | 2024-10-22 | — | — | US | claimed |
| US-20230416286-A1 | INHIBITORS OF MEK KINASE | MOSAICA MEDICINES, INC. | 2023-12-28 | — | — | US | claimed |
| US-20250250293-A1 | INHIBITORS OF MEK KINASE | MOSAICA MEDICINES, INC. | 2025-08-07 | — | — | US | disclosed |
| WO-2025032211-A1 | TREATMENT OF CANCER WITH A RAF INHIBITOR | PIERRE FABRE MEDICAMENT (FR) | 2025-02-13 | — | — | WO | disclosed |
| EP-4486750-A1 | INHIBITORS OF MEK KINASE | Kinnate Biopharma Inc. (US) | 2025-01-08 | — | — | EP | disclosed |
| CN-119137130-A | Inhibitors of MEK kinase | 金耐特生物制药公司 | 2024-12-13 | — | — | CN | disclosed |
| US-12122800-B2 | Inhibitors of MEK kinase | KINNATE BIOPHARMA INC. (US) | 2024-10-22 | — | — | US | disclosed |
| US-20230416286-A1 | INHIBITORS OF MEK KINASE | MOSAICA MEDICINES, INC. | 2023-12-28 | — | — | US | disclosed |
| US-11780862-B2 | Inhibitors of MEK kinase | KINNATE BIOPHARMA INC. (US) | 2023-10-10 | — | — | US | disclosed |
| US-11780862-B2 | Inhibitors of MEK kinase | KINNATE BIOPHARMA INC. (US) | 2023-10-10 | — | — | US | disclosed |
| US-11780862-B2 | Inhibitors of MEK kinase | KINNATE BIOPHARMA INC. (US) | 2023-10-10 | — | — | US | disclosed |
| WO-2023168203-A1 | INHIBITORS OF MEK KINASE | KINNATE BIOPHARMA INC. (US) | 2023-09-07 | — | — | WO | disclosed |
| WO-2023168203-A1 | INHIBITORS OF MEK KINASE | KINNATE BIOPHARMA INC. (US) | 2023-09-07 | — | — | WO | disclosed |
| US-20230279033-A1 | INHIBITORS OF MEK KINASE | MOSAICA MEDICINES, INC. | 2023-09-07 | — | — | US | disclosed |
| US-20230279033-A1 | INHIBITORS OF MEK KINASE | MOSAICA MEDICINES, INC. | 2023-09-07 | — | — | US | disclosed |
| US-20230279033-A1 | INHIBITORS OF MEK KINASE | MOSAICA MEDICINES, INC. | 2023-09-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230279033-A1 | INHIBITORS OF MEK KINASE | BRAF, NRAS, RAF1 | MAP2K1 35/4885MAP2K2 27/4885PRKCZ 641/4885 |
| US-12122800-B2 | Inhibitors of MEK kinase | BRAF, NRAS, RAF1 | MAP2K1 35/4885MAP2K2 27/4885PRKCZ 641/4885 |
| US-20250250293-A1 | INHIBITORS OF MEK KINASE | BRAF, NRAS, RAF1 | MAP2K1 35/4885MAP2K2 27/4885PRKCZ 641/4885 |
| US-20230416286-A1 | INHIBITORS OF MEK KINASE | BRAF, NRAS, RAF1 | MAP2K1 35/4885MAP2K2 27/4885PRKCZ 641/4885 |
| US-11780862-B2 | Inhibitors of MEK kinase | BRAF, NRAS, RAF1 | MAP2K1 35/4885MAP2K2 27/4885PRKCZ 641/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.